Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2015, Article ID 761378, 8 pages
http://dx.doi.org/10.1155/2015/761378
Research Article

Increased NY-ESO-1 Expression and Reduced Infiltrating CD3+ T Cells in Cutaneous Melanoma

1Department of Dermatology, University of São Paulo, Avenida Dr. Enéas de Carvalho Aguiar 255, 3° Andar, 05403-900 São Paulo, SP, Brazil
2Division of Clinical Immunology and Allergy, University of São Paulo, Avenida Dr. Enéas de Carvalho Aguiar 255, 8° Andar, 05403-900 São Paulo, SP, Brazil
3MGH Biostatistics Center, 50 Staniford Street, Suite 560, Boston, MA 02114, USA
4Dermatopathology Unit, Pathology Service, Massachusetts General Hospital, Harvard Medical School, Warren Building 825, 55 Fruit Street, Boston, MA 02114, USA

Received 5 February 2015; Revised 23 March 2015; Accepted 29 March 2015

Academic Editor: Shigeo Koido

Copyright © 2015 Mara Giavina-Bianchi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. B. K. Armstrong and A. Kricker, “Cutaneous melanoma,” Cancer Surveys, vol. 19-20, pp. 219–240, 1994. View at Google Scholar · View at Scopus
  2. E. Linos, S. M. Swetter, M. G. Cockburn, G. A. Colditz, and C. A. Clarke, “Increasing burden of melanoma in the United States,” Journal of Investigative Dermatology, vol. 129, no. 7, pp. 1666–1674, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. G. Pellacani, G. Lo Scocco, M. Vinceti et al., “Melanoma epidemic across the millennium: time trends of cutaneous melanoma in Emilia-Romagna (Italy) from 1997 to 2004,” Journal of the European Academy of Dermatology and Venereology, vol. 22, no. 2, pp. 213–218, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. A. J. Stratigos, A. M. Forsea, R. J. T. van der Leest et al., “Euromelanoma: a dermatology-led European campaign against nonmelanoma skin cancer and cutaneous melanoma. Past, present and future,” British Journal of Dermatology, vol. 167, supplement 2, pp. 99–104, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. H. B. Neuman, A. Patel, N. Ishill et al., “A single-institution validation of the AJCC staging system for stage IV melanoma,” Annals of Surgical Oncology, vol. 15, no. 7, pp. 2034–2041, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. P. B. Chapman, A. Hauschild, C. Robert et al., “Improved survival with vemurafenib in melanoma with BRAF V600E mutation,” The New England Journal of Medicine, vol. 364, no. 26, pp. 2507–2516, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. M. C. Fox, C. D. Lao, J. L. Schwartz, M. L. Frohm, C. K. Bichakjian, and T. M. Johnson, “Management options for metastatic melanoma in the era of novel therapies: a primer for the practicing dermatologist: part I: management of stage III disease,” Journal of the American Academy of Dermatology, vol. 68, no. 1, pp. 1.e1–1.e12, 2013. View at Google Scholar
  8. F. S. Hodi, S. J. O'Day, D. F. McDermott et al., “Improved survival with ipilimumab in patients with metastatic melanoma,” The New England Journal of Medicine, vol. 363, no. 8, pp. 711–723, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. U. Keilholz, C. J. A. Punt, M. Gore et al., “Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group,” Journal of Clinical Oncology, vol. 23, no. 27, pp. 6747–6755, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. C. Robert, L. Thomas, I. Bondarenko et al., “Ipilimumab plus dacarbazine for previously untreated metastatic melanoma,” The New England Journal of Medicine, vol. 364, no. 26, pp. 2517–2526, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Juretic, G. C. Spagnoli, E. Schultz-Thater, and B. Sarcevic, “Cancer/testis tumour-associated antigens: immunohistochemical detection with monoclonal antibodies,” The Lancet Oncology, vol. 4, no. 2, pp. 104–109, 2003. View at Publisher · View at Google Scholar · View at Scopus
  12. A. J. G. Simpson, O. L. Caballero, A. Jungbluth, Y.-T. Chen, and L. J. Old, “Cancer/testis antigens, gametogenesis and cancer,” Nature Reviews Cancer, vol. 5, no. 8, pp. 615–625, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. I. D. Davis, W. Chen, H. Jackson et al., “Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 29, pp. 10697–10702, 2004. View at Publisher · View at Google Scholar · View at Scopus
  14. S. Gnjatic, E. Jäger, W. Chen et al., “CD8+ T cell responses against a dominant cryptic HLA-A2 epitope after NY-ESO-1 peptide immunization of cancer patients,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 18, pp. 11813–11818, 2002. View at Publisher · View at Google Scholar · View at Scopus
  15. E. Jäger, S. Gnjatic, Y. Nagata et al., “Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 22, pp. 12198–12203, 2000. View at Publisher · View at Google Scholar · View at Scopus
  16. S. A. Rosenberg, “Shedding light on immunotherapy for cancer,” The New England Journal of Medicine, vol. 350, no. 14, pp. 1461–1463, 2004. View at Publisher · View at Google Scholar · View at Scopus
  17. A. M. Scott and J. Cebon, “Clinical promise of tumour immunology,” The Lancet, vol. 349, supplement 2, pp. SII19–SII22, 1997. View at Google Scholar · View at Scopus
  18. S. Fujita, H. Wada, A. A. Jungbluth et al., “NY-ESO-1 expression and immunogenicity in esophageal cancer,” Clinical Cancer Research, vol. 10, no. 19, pp. 6551–6558, 2004. View at Publisher · View at Google Scholar · View at Scopus
  19. J. Konishi, S. Toyooka, M. Aoe et al., “The relationship between NY-ESO-1 mRNA expression and clinicopathological features in non-small cell lung cancer,” Oncology Reports, vol. 11, no. 5, pp. 1063–1067, 2004. View at Google Scholar · View at Scopus
  20. T. Nakada, Y. Noguchi, S. Satoh et al., “NY-ESO-1 mRNA expression and immunogenicity in advanced prostate cancer,” Cancer Immun, vol. 3, article 10, 2003. View at Google Scholar · View at Scopus
  21. J.-R. Peng, H.-S. Chen, D.-C. Mou et al., “Expression of cancer/testis (CT) antigens in Chinese hepatocellular carcinoma and its correlation with clinical parameters,” Cancer Letters, vol. 219, no. 2, pp. 223–232, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. Y. Wang, X. J. Wu, A. L. Zhao et al., “Cancer/testis antigen expression and autologous humoral immunity to NY-ESO-1 in gastric cancer,” Cancer Immunity, vol. 4, p. 11, 2004. View at Google Scholar
  23. D. A. Chitale, A. A. Jungbluth, D. S. Marshall et al., “Expression of cancer-testis antigens in endometrial carcinomas using a tissue microarray,” Modern Pathology, vol. 18, no. 1, pp. 119–126, 2005. View at Publisher · View at Google Scholar · View at Scopus
  24. J. A. Hemminger, A. Ewart Toland, T. J. Scharschmidt et al., “The cancer-testis antigen NY-ESO-1 is highly expressed in myxoid and round cell subset of liposarcomas,” Modern Pathology, vol. 26, no. 2, pp. 282–288, 2013. View at Publisher · View at Google Scholar · View at Scopus
  25. T. Kurashige, Y. Noguchi, T. Saika et al., “NY-ESO-1 expression and immunogenicity associated with transitional cell carcinoma: correlation with tumor grade,” Cancer Research, vol. 61, no. 12, pp. 4671–4674, 2001. View at Google Scholar · View at Scopus
  26. K. Odunsi, A. A. Jungbluth, E. Stockert et al., “NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer,” Cancer Research, vol. 63, no. 18, pp. 6076–6083, 2003. View at Google Scholar · View at Scopus
  27. H. A. Vaughae, S. Svobodova, D. MacGregor et al., “Immunohistochemical and molecular analysis of human melanomas for expression of the human cancer-testis antigens NY-ESO-1 and LAGE-1,” Clinical Cancer Research, vol. 10, no. 24, pp. 8396–8404, 2004. View at Publisher · View at Google Scholar · View at Scopus
  28. S. Svobodová, J. Browning, D. MacGregor et al., “Cancer-testis antigen expression in primary cutaneous melanoma has independent prognostic value comparable to that of Breslow thickness, ulceration and mitotic rate,” European Journal of Cancer, vol. 47, no. 3, pp. 460–469, 2011. View at Publisher · View at Google Scholar · View at Scopus
  29. C. Barrow, J. Browning, D. MacGregor et al., “Tumor antigen expression in melanoma varies according to antigen and stage,” Clinical Cancer Research, vol. 12, no. 3 I, pp. 764–771, 2006. View at Publisher · View at Google Scholar · View at Scopus
  30. J. S. Goydos, M. Patel, and W. Shih, “NY-ESO-1 and CTp11 expression may correlate with stage of progression in melanoma,” Journal of Surgical Research, vol. 98, no. 2, pp. 76–80, 2001. View at Publisher · View at Google Scholar · View at Scopus
  31. E. F. Velazquez, A. A. Jungbluth, M. Yancovitz et al., “Expression of the cancer/testis antigen NY-ESO-1 in primary and metastatic malignant melanoma (MM)—correlation with prognostic factors,” Cancer Immunity, vol. 7, article 11, 2007. View at Google Scholar · View at Scopus
  32. T. Boon and L. J. Old, “Cancer tumor antigens,” Current Opinion in Immunology, vol. 9, no. 5, pp. 681–683, 1997. View at Publisher · View at Google Scholar
  33. B. Weide, H. Zelba, E. Derhovanessian et al., “Functional T cells targeting NY-ESO-1 or Melan-A are predictive for survival of patients with distant melanoma metastasis,” Journal of Clinical Oncology, vol. 30, no. 15, pp. 1835–1841, 2012. View at Publisher · View at Google Scholar · View at Scopus
  34. A. Piris, A. C. Lobo, and L. M. Duncan, “Melanoma staging: where are we now?” Dermatologic Clinics, vol. 30, no. 4, pp. 581–592, 2012. View at Publisher · View at Google Scholar · View at Scopus
  35. C. S. Kasper and M. D. Tharp, “Quantification of cutaneous mast cells using morphometric point counting and a conjugated avidin stain,” Journal of the American Academy of Dermatology, vol. 16, no. 2 I, pp. 326–331, 1987. View at Publisher · View at Google Scholar · View at Scopus
  36. L. M. Duncan, L. A. Richards, and M. C. Mihm Jr., “Increased mast cell density in invasive melanoma,” Journal of Cutaneous Pathology, vol. 25, no. 1, pp. 11–15, 1998. View at Publisher · View at Google Scholar · View at Scopus
  37. M. Lüftl, G. Schuler, and A. A. Jungbluth, “Melanoma or not? Cancer testis antigens may help,” British Journal of Dermatology, vol. 151, no. 6, pp. 1213–1218, 2004. View at Publisher · View at Google Scholar · View at Scopus
  38. V. C. C. Andrade, A. L. Vettore, R. S. Felix et al., “Prognostic impact of cancer/testis antigen expression in advanced stage multiple myeloma patients,” Cancer Immunity, vol. 8, article 2, 2008. View at Google Scholar · View at Scopus
  39. S. Krüger, V. Ola, A. C. Feller, D. Fischer, and M. Friedrich, “Expression of cancer-testis antigen CT7 (MAGE-C1) in breast cancer: an immunohistochemical study with emphasis on prognostic utility,” Pathology and Oncology Research, vol. 13, no. 2, pp. 91–96, 2007. View at Publisher · View at Google Scholar · View at Scopus
  40. E. Yakirevich, E. Sabo, O. Lavie, S. Mazareb, G. C. Spagnoli, and M. B. Resnick, “Expression of the MAGE-A4 and NY-ESO-1 Cancer-Testis Antigens in Serous Ovarian Neoplasms,” Clinical Cancer Research, vol. 9, no. 17, pp. 6453–6460, 2003. View at Google Scholar · View at Scopus
  41. A. Oberthuer, B. Hero, R. Spitz, F. Berthold, and M. Fischer, “The tumor-associated antigen PRAME is universally expressed in high-stage neuroblastoma and associated with poor outcome,” Clinical Cancer Research, vol. 10, no. 13, pp. 4307–4313, 2004. View at Publisher · View at Google Scholar · View at Scopus
  42. F. Azimi, R. A. Scolyer, P. Rumcheva et al., “Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma,” Journal of Clinical Oncology, vol. 30, no. 21, pp. 2678–2683, 2012. View at Publisher · View at Google Scholar · View at Scopus
  43. W. H. Clark Jr., D. E. Elder, D. Guerry IV et al., “Model predicting survival in stage I melanoma based on tumor progression,” Journal of the National Cancer Institute, vol. 81, no. 24, pp. 1893–1904, 1989. View at Publisher · View at Google Scholar · View at Scopus
  44. C. G. Clemente, M. C. Mihm Jr., R. Bufalino, S. Zurrida, P. Collini, and N. Cascinelli, “Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma,” Cancer, vol. 77, no. 7, pp. 1303–1310, 1996. View at Publisher · View at Google Scholar · View at Scopus
  45. N. E. Thomas, K. J. Busam, L. From et al., “Tumor-infiltrating lymphocyte grade in primary melanomas is independently associated with melanoma-specific survival in the population-based genes, environment and melanoma study,” Journal of Clinical Oncology, vol. 31, no. 33, pp. 4252–4259, 2013. View at Publisher · View at Google Scholar · View at Scopus
  46. M. J. M. Gooden, G. H. de Bock, N. Leffers, T. Daemen, and H. W. Nijman, “The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis,” British Journal of Cancer, vol. 105, no. 1, pp. 93–103, 2011. View at Publisher · View at Google Scholar · View at Scopus
  47. I. S. van Houdt, B. J. R. Sluijter, L. M. Moesbergen et al., “Favorable outcome in clinically stage II melanoma patients is associated with the presence of activated tumor infiltrating T-lymphocytes and preserved MHC class I antigen expression,” International Journal of Cancer, vol. 123, no. 3, pp. 609–615, 2008. View at Publisher · View at Google Scholar · View at Scopus
  48. F. Piras, R. Colombari, L. Minerba et al., “The predictive value of CD8, CD4, CD68, and human leukocyte antigen-D-related cells in the prognosis of cutaneous malignant melanoma with vertical growth phase,” Cancer, vol. 104, no. 6, pp. 1246–1254, 2005. View at Publisher · View at Google Scholar · View at Scopus
  49. K. Odunsi, J. Matsuzaki, J. Karbach et al., “Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 15, pp. 5797–5802, 2012. View at Publisher · View at Google Scholar · View at Scopus